Autologous T cell therapy for PRAME⁺ advanced solid tumors in HLA-A*02⁺ patients: a phase 1 trial.

ABSTRACT: In contrast to chimeric antigen receptor T cells, T cell receptor (TCR)-engineered T cells can target intracellular tumor-associated antigens crucial for treating solid tumors. However, most trials published so far show limited clinical activity. Here we report interim data from a first-in-human, multicenter, open-label, 3 + 3 dose-escalation/de-escalation phase 1 trial studying IMA203, an autologous preferentially expressed antigen in melanoma (PRAME)-directed TCR T cell therapy in HLA-A*02⁺ patients with PRAME⁺ recurrent and/or refractory solid tumors, including melanoma and sarcoma. Primary objectives include the evaluation of safety and tolerability and the determination of the maximum tolerated dose (MTD) and/or recommended dose for extension. Secondary objective

SUBMITTER: Wermke M 

PROVIDER: S-EPMC12283372 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature